Novo Nordisk shares plunge after Wegovy-maker cuts full-year guidance
Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.
Nurphoto | Nurphoto | Getty Images
Danish pharmaceutical giant Novo Nordisk on Tuesday cuts its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market.
Shares were down 15% at 12:11 p.m. London time, shortly after the announcement.
This is a developing story. Please check back for updates.
<
